Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

PHASE I CLINICAL TRIAL OF SYH2092 INJECTION FOR WEIGHT MANAGEMENT IN ADULT PATIENTS WITH OVERWEIGHT OR OBESITY OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHINA

The Board of Directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the Phase I clinical trial of the SYH2092 injection (the "**Product**") developed by the Group for weight management in adult patients with overweight or obesity has been officially initiated at the first centre in China.

The Product is an amylin receptor agonist. By optimising its agonistic activity, it has the potential to improve efficacy with a manageable tolerability profile. In addition, through the optimisation of fatty acid modification, it prolongs the *in vivo* half-life which has the potential to translate to a durable weight loss benefit. Preclinical studies showed that, compared with several amylin analogues currently in clinical development, the Product demonstrated higher target agonistic activity, potent weight-reducing efficacy, and a prolonged weight-loss maintenance effect.

The Group obtained the Notice of Approval for Clinical Trial of Drug from the National Medical Products Administration of the People's Republic of China in August 2026, and initiated the Phase I clinical trial of the Product following the approval. This Phase I clinical trial aims to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of the Product in healthy participants.

The Product has the potential to bring significant clinical benefits for weight management in patients with obesity, and improve glycaemic control in adult patients with type 2 diabetes mellitus (T2DM). The recruitment and screening of participants for this Phase I clinical trial are actively underway.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 31 August 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.